AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma

NCT03893903 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Malignant Glioma

Interventions

DRUG: IDH1R132H peptide vaccine
DRUG: Avelumab

Sponsor

German Cancer Research Center